Skip to main content
. 2012 Dec 7;7(12):e50325. doi: 10.1371/journal.pone.0050325

Figure 3. Effect of quarterly albendazole from age 15 months to 5 years on infectious disease incidence in children.

Figure 3

Kaplan-Meier survival estimates for time to first (or only episode) of (a) malaria, (b) diarrhoea and (c) pneumonia during the intervention period, comparing children who received quarterly albendazole with those who received placebo. Numbers shown in the tables are number of events (in brackets) and number of children at risk.